Please assess the completion status of the following clinical trial:

Trial Title: Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of pulmonary sarcoidosis for ≥6 months (cutaneous and ocular involvement allowed), defined as:~  * Histologically proven diagnosis of sarcoidosis by bronchoscopy, biopsy (any organ) or bronchioalveolar lavage~ * Parenchymal lung involvement by historical radiological evidence~* Must have symptomatic and/or active pulmonary sarcoidosis as evidenced by:~  * Modified Medical Research Council Dyspnea Scale grade of \>= 1; and~ * Forced vital capacity ≥50%; and~* Receiving treatment with 10 to 25 mg/day of oral prednisone (or equivalent), at a stable dose for ≥4 weeks prior to Day 1, and capable of undergoing the protocol-specified steroid taper regimen.~* Body weight ≥45 kg and \<160 kg.~Key Exclusion Criteria:~* Current disease presentation consistent with Lofgren's syndrome.~* History of severe allergic or anaphylactic reactions to therapeutic proteins or known sensitivity to efzofitimod or to its inactive components (L-histidine, sodium chloride, sucrose, L-methionine, and polysorbate-20).~* Treatment with biological immunomodulators such as tumor necrosis factor-alpha inhibitors.~* Current evidence of clinically significant cardiovascular, hepatic, renal, hematological, metabolic, or gastrointestinal disease, or has a condition that requires other treatment.~* Clinically significant pulmonary hypertension requiring vasodilator treatment.~* Any history of tuberculosis or evidence of active systemic non-tuberculosis fungal or mycobacterial infection within 1 year of Screening.~* History of clinically significant cardiac, neurological, gastrointestinal, and/or renal manifestations of sarcoidosis.~* Any condition that necessitated hospitalization within the 3 months prior to Day 1 or is likely to require so during the study.~* Participation in another clinical study of an investigational agent or device within 3 months (small molecules) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer.~* History of or positive results of screening for hepatitis B, hepatitis C or human immunodeficiency virus.~* Is an active, heavy smoker of tobacco/nicotine-containing products (defined as \>20 cigarettes/day or e-cigarette equivalent).~* Active substance abuse or history of substance abuse within the 12 months prior to Screening.~* Participant has received a live vaccination within 8 weeks before Day 1 or inoculation with a live vaccine is planned during study participation.~* Positive for Jo-1 antibodies (Ab) at Screening, or past history of Jo-1 Ab positivity.~* Significant and/or acute illness within 5 days prior to drug administration that may impact safety assessments, in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to efzofitimod via intravenous (IV) infusion every 4 weeks until Week 20.
- Efzofitimod 1.0 mg/kg (Type: EXPERIMENTAL): Participants will receive efzofitimod 1.0 milligrams/kilogram (mg/kg) via IV infusion every 4 weeks until Week 20.
- Efzofitimod 3.0 mg/kg (Type: EXPERIMENTAL): Participants will receive efzofitimod 3.0 mg/kg via IV infusion every 4 weeks until Week 20.
- Efzofitimod 5.0 mg/kg (Type: EXPERIMENTAL): Participants will receive efzofitimod 5.0 mg/kg via IV infusion every 4 weeks until Week 20.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete